Twist Bioscience Corporation (TWST) Income Statement
TWST FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsTWST revenue and net income
Where TWST's revenue goes
FY2025Each bar shows an amount and its share of revenue. TWST kept −20.6% of revenue as net income.
TWST profit margins
TWST growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +20.3% | +22.8% | +33.1% | — |
| Gross profit | +43.2% | +31.4% | +46.1% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TWST quarterly EPS vs estimates
Twist Bioscience beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.44).
TWST income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M | $132.3M | $90.1M | $54.4M | $25.4M | $10.8M | $2.3M |
| Cost of revenue | $185.6M | $179.6M | $155.4M | $119.3M | $80.6M | $61.4M | $47.4M | $32.2M | $24.0M | $9.4M |
| Gross profit | $191.0M | $133.3M | $89.7M | $84.2M | $51.7M | $28.7M | $7.0M | −$6.8M | −$13.3M | −$7.2M |
| Research & development | $80.3M | $90.9M | $106.9M | $120.3M | $69.1M | $43.0M | $35.7M | $20.3M | $19.2M | $18.2M |
| Sales, general & admin | $247.0M | $218.4M | $189.7M | $212.9M | $135.9M | $103.3M | $80.1M | $43.5M | $26.1M | $18.3M |
| Total operating expenses | $327.3M | $354.2M | $306.9M | $333.3M | $204.4M | $168.8M | $115.8M | $63.8M | $45.2M | $36.5M |
| Operating income | −$136.3M | −$220.8M | −$217.2M | −$249.0M | −$152.7M | −$140.1M | −$108.8M | −$70.6M | −$58.5M | −$43.7M |
| Interest income | $11.4M | $15.3M | $14.4M | $3.1M | $435,000 | $1.5M | $3.0M | $999,000 | $412,000 | $241,000 |
| Interest expense | — | $29,000 | $5,000 | $80,000 | $367,000 | $787,000 | $1.3M | $1.3M | $905,000 | $746,000 |
| Income before taxes | −$77.0M | −$208.2M | −$203.5M | −$228.3M | −$154.0M | −$139.5M | −$107.4M | −$71.0M | −$59.0M | −$44.1M |
| Income taxes | $719,000 | $560,000 | $1.2M | −$10.4M | −$1.9M | $382,000 | $292,000 | $242,000 | $280,000 | $819,000 |
| Net income | −$77.7M | −$208.7M | −$204.6M | −$217.9M | −$152.1M | −$139.9M | −$107.7M | −$71.2M | −$59.3M | −$44.1M |
| EBITDA | −$52.1M | −$176.7M | −$174.2M | −$247.0M | −$143.9M | −$132.1M | −$100.0M | −$64.0M | −$53.1M | −$39.1M |
| EPS (diluted) | −$2.11 | −$2.83 | −$3.64 | −$4.07 | −$3.12 | −$3.06 | −$3.99 | −$7.25 | −$3.16 | −$22.04 |
| Gross margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | 31.8% | 12.8% | −26.6% | −123.1% | −315.2% |
| Operating margin | −36.2% | −70.6% | −88.6% | −122.3% | −115.4% | −155.5% | −200.1% | −277.5% | −543.2% | −1,924.0% |
| Net margin | −20.6% | −66.7% | −83.5% | −107.0% | −114.9% | −155.3% | −198.0% | −280.2% | −550.8% | −1,943.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $118.4M | $110.7M | $103.7M | $99.0M | $96.1M | $92.8M | $88.7M | $84.7M | $81.5M | $75.3M | $71.5M | $66.9M |
| Cost of revenue | $55.9M | $53.6M | $49.7M | $48.2M | $44.8M | $46.8M | $45.9M | $46.5M | $46.2M | $44.4M | $42.5M | $42.4M |
| Gross profit | $62.5M | $57.1M | $54.0M | $50.8M | $51.3M | $46.0M | $42.8M | $38.2M | $35.3M | $30.9M | $29.0M | $24.5M |
| Research & development | $18.0M | $19.7M | $17.1M | $17.0M | $18.0M | $23.9M | $21.3M | $21.1M | $22.5M | $24.1M | $23.1M | $23.7M |
| Sales, general & admin | $80.7M | $76.1M | $69.9M | $63.8M | $63.4M | $63.7M | $56.2M | $53.1M | $56.8M | $55.6M | $52.8M | $47.4M |
| Total operating expenses | $98.7M | $95.8M | $86.9M | $80.8M | $81.4M | $87.6M | $77.5M | $74.3M | $124.2M | $79.8M | $75.9M | $74.6M |
| Operating income | −$36.3M | −$38.7M | −$32.9M | −$29.9M | −$30.1M | −$41.6M | −$34.6M | −$36.0M | −$88.9M | −$48.9M | −$47.0M | −$50.1M |
| Interest income | $1.5M | $1.7M | $2.2M | $2.6M | $2.7M | $2.8M | $3.2M | $3.6M | $3.7M | $3.9M | $4.1M | $3.9M |
| Interest expense | — | — | — | — | — | $143,000 | $24,000 | $29,000 | $0 | $0 | $0 | $1,000 |
| Income before taxes | −$34.7M | −$44.0M | −$30.3M | −$26.9M | $20.6M | −$39.2M | −$31.5M | −$34.6M | −$85.4M | −$45.1M | −$42.9M | −$46.5M |
| Income taxes | −$311,000 | $43,000 | $253,000 | $256,000 | $191,000 | $175,000 | $97,000 | −$96,000 | $191,000 | $345,000 | $120,000 | −$222,000 |
| Net income | −$35.1M | −$44.0M | −$30.5M | −$27.1M | $20.4M | −$39.3M | −$31.6M | −$34.7M | −$85.6M | −$45.5M | −$43.0M | −$46.2M |
| EBITDA | −$28.0M | −$32.2M | −$26.7M | −$20.9M | $26.6M | −$32.6M | −$25.1M | −$28.1M | −$77.1M | −$36.8M | −$34.7M | −$38.0M |
| EPS (diluted) | −$0.56 | −$0.60 | −$0.50 | −$0.45 | −$0.47 | −$0.66 | −$0.53 | −$0.59 | −$0.70 | −$0.79 | −$0.75 | −$0.75 |
| Gross margin | 52.8% | 51.6% | 52.0% | 51.3% | 53.4% | 49.6% | 48.3% | 45.1% | 43.3% | 41.0% | 40.5% | 36.6% |
| Operating margin | −30.6% | −34.9% | −31.7% | −30.2% | −31.4% | −44.8% | −39.1% | −42.5% | −109.2% | −64.9% | −65.7% | −74.9% |
| Net margin | −29.6% | −39.8% | −29.4% | −27.4% | 21.2% | −42.4% | −35.6% | −40.9% | −105.0% | −60.4% | −60.2% | −69.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TWST's financial statements (latest annual report filed November 17, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TWST financial results
In fiscal year 2025 (ended September 30, 2025), Twist Bioscience reported revenue of $376.6 million, up 20.3% from the year before. It had a net loss of $77.7 million, a net profit margin of −20.6%. Diluted earnings per share came to −$2.11. Over five years revenue grew at an average rate of 33.1% a year.
See the TWST stock overview for the latest quote and news, or the TWST chart for price history and technical indicators.
TWST income statement FAQ
What is Twist Bioscience's annual revenue?
Twist Bioscience reported total revenue of $376.6 million for fiscal year 2025, which ended on September 30, 2025. That was up 20.3% from $313.0 million the previous year.
Is Twist Bioscience profitable?
No. Twist Bioscience reported a net loss of $77.7 million in fiscal 2025, a net profit margin of −20.6%; its operating margin was −36.2%.
What is Twist Bioscience's gross margin?
Twist Bioscience's gross margin was 50.7% in fiscal 2025: for every $100 of revenue, Twist Bioscience kept $51 after the direct cost of its products and services.
How much does Twist Bioscience spend on research and development?
Twist Bioscience spent $80.3 million on research and development in fiscal 2025, 21.3% of revenue.
How fast is Twist Bioscience growing?
Revenue grew 33.1% a year on average over the last five fiscal years, from $90.1 million to $376.6 million.
What are Twist Bioscience's earnings per share?
Twist Bioscience earned $-2.11 per diluted share in fiscal 2025, compared with $-2.83 a year earlier.
When will Twist Bioscience report its next earnings?
Twist Bioscience is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Twist Bioscience's fiscal year end?
Twist Bioscience's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on November 17, 2025.